Table 1

Baseline characteristics of the P4O2 COVID-19 cohort

All patients (N=95)
General characteristics
 Sex (female)47/95 (49.5%)
 Age (years)54.1±6.2
 BMI (kg/m2)n=94; 30.5±5.3
Comorbidities
 Asthma16/94 (17.0%)
 COPD6/94 (6.4%)
 CVD27/93 (29.0%)
 Diabetes15/94 (16.0%)
Symptom categories
 Fatigue66/95 (69.5%)
 Respiratory75/95 (78.9%)
 Neurological67/95 (70.5%)
 Cardiovascular25/95 (26.3%)
 Gastrointestinal29/95 (30.5%)
 Other18/95 (18.9%)
Lung function
 FEV1 % predn=90; 91.5±17.1
 FVC % predn=90; 89.8±18.1
 FEV1/FVCn=90; 80.1±8.0
 DLCO % predn=89; 79.9±19.9
Questionnaires
 FSSn=87; 5.6 (4.2, 6.3)
 PROMISn=82; 28.7±8.0
 PC-PTSD-5n=83; 1.0 (0.0, 2.0)
 EQ5Dn=83; 9.0 (6.0, 11.0)
 CLC-ICn=80; 5.0 (2.0, 8.0)
 USER-Pn=83; 80.0 (60.0, 96.8)
 HADS Depressionn=78; 3.5 (1.0, 7.8)
 HADS Anxietyn=80; 4.0 (1.0, 8.0)
Acute phase WHO severity
 Mild10/95 (10.5%)
 Moderate61/95 (64.2%)
 Severe24/95 (25.3%)
Acute phase duration/complications
 Hospital durationn=84; 8.0 (5.0, 15.2)
 Pulmonary embolism15/92 (16.3%)
 Thrombosis14/91 (15.4%)
Dominant virus type
 Alpha43/95 (45.3%)
 Delta41/95 (43.2%)
 Omicron11/95 (11.6%)
CT abnormalities
 Ground-glass opacity/consolidations54/87 (62.1%)
 Bronchiectasis19/87 (21.8%)
 Subpleural reticulation23/87 (26.4%)
 Honeycombing2/87 (2.3%)
 Lymphadenopathy9/87 (10.3%)
 Airtrapping10/87 (11.5%)
Vaccination
 No28/95 (29.5%)
 Yes, 1 or more doses67/95 (70.5%)
Smoking status
 Never smoker40/95 (42.1%)
 Ex-smoker51/95 (53.7%)
 Current smoker4/95 (4.2%)
Level of education
 Secondary education19/79 (24.1%)
 Vocational education33/79 (41.8%)
 Bachelor19/79 (24.1%)
 Master8/79 (10.1%)
  • For numerical values, normally distributed data is given as mean±SD, otherwise as median (IQR). Categorical variables are displayed as n (%). When not all data is available, the number of patients with data available is given.

  • BMI, body mass index; CLC-IC, Checklist for Cognitive Consequences after an ICU Admission; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; DLCO, diffusion capacity of the lungs for carbon monoxide; EQ5D, EuroQoL 5D-5L; FEV1, forced expiratory volume in 1 s; FSS, Fatigue Severity Scale; FVC, forced vital capaticy; HADS, Hospital Anxiety and Depression Scale; PC-PTSD-5, Primary Care PTSD Screen for DSM-5; PROMIS, Patient-Reported Outcomes Measurement Information System; USER-P, Utrecht Scale for Evaluation of Revalidation-Participation.